Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multicenter, open-label, single-arm, phase II study

被引：0
|
作者：
Peng, Peijian
Xu, Xiaolu
Zhong, Jincai
Ye, Jin-Hui
Wang, Zhi-Hui
Wang, Hong
Lin, Hong
Du, Caiwen
Zou, Guorong
Ouyang, Jie
Shi, Ying-ying
Xu, Fei
Yu, Gengsheng
Lu, Yongkui
Wang, Yong-Xia
Cui, Shi-En
Li, Lu-Zhen
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Canc, Dept Breast Dis, Zhuhai, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China
[3] First Peoples Hosp Zhaoqing, Dept Breast Oncol, Zhaoqing, Peoples R China
[4] Jiangmen Cent Hosp, Jiangmen, Peoples R China
[5] Zhuhai Matern & Child Hlth Hosp, Dept Breast Surg, Zhuhai, Guangdong, Peoples R China
[6] Zhuhai Hosp Integrated Tradit Chinese & Western M, Dept Breast Dis, Zhuhai, Guangdong, Peoples R China
[7] Chinese Acad Med Sci, Canc Hosp, Shenzhen Ctr, Shenzhen, Peoples R China
[8] Panyu Cent Hosp, Guangzhou, Peoples R China
[9] Dongguan Peoples Hosp 3, Dongguan, Peoples R China
[10] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China
[11] State Key Lab Oncol South China, Guangzhou, Peoples R China
[12] Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[13] Guangxi Med Univ Canc Ctr, Guangxi, Peoples R China
[14] Dongguan Peoples Hosp, Dongguan, Peoples R China
[15] Zhongshan City Peoples Hosp, Dept Gen Surg, Breast Ctr, Zhongshan, Peoples R China
[16] Guangzhou Univ Tradit Chinese Med, Zhongshan Hosp Tradit Chinese Med, Zhongshan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13139
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial
    Kenichi Inoue
    Jun Ninomiya
    Tsuyoshi Saito
    Katsuhiko Okubo
    Takashi Nakakuma
    Hirofumi Yamada
    Kei Kimizuka
    Tohru Higuchi
    Investigational New Drugs, 2019, 37 : 592 - 593
  • [32] Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial
    Huh, Gunn
    Lee, Hee Seung
    Choi, Jin Ho
    Lee, Sang Hyub
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Bang, Seungmin
    Lee, Eaum Seok
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [33] Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
    Park, Yeon Hee
    Im, Seock-Ah
    Kim, Sung-Bae
    Sohn, Joo Hyuk
    Lee, Keun Seok
    Chae, Yee Soo
    Lee, Ki Hyeong
    Kim, Jee Hyun
    Im, Young-Hyuck
    Kim, Ji-Yeon
    Kim, Tae-Yong
    Lee, Kyung-Hun
    Ahn, Jin-Hee
    Kim, Gun Min
    Park, In Hae
    Lee, Soo Jung
    Han, Hye Sook
    Kim, Se Hyun
    Jung, Kyung Hae
    EUROPEAN JOURNAL OF CANCER, 2017, 86 : 385 - 393
  • [34] TORIPALIMAB PLUS CHEMORADIOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER: A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL
    Xu, Xiaoting
    Huan, Jian
    Miao, Hui
    Wang, Hao
    Wang, Yue
    Zhu, Hongyu
    Jiang, Jun
    Zhou, Juying
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A384 - A384
  • [35] Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label Multicenter Single-Arm Phase II Study
    Spigel, David R.
    Waterhouse, David M.
    Lane, Steve
    Legenne, Philippe
    Bhatt, Kamal
    CLINICAL LUNG CANCER, 2013, 14 (04) : 356 - 363
  • [36] Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study
    Li Yanwei
    Feng, He
    Ren, Peng
    Yue, Jie
    Zhang, Wencheng
    Tang, Peng
    Shang, Xiaobin
    Pang, Qingsong
    Liu, Dongying
    Chen, Chuangui
    Pan, Zhanyu
    Tao, Yu Zhen
    ONCOLOGIST, 2020, 25 (10): : E1464 - E1472
  • [37] Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
    Mao, Lili
    Fang, Meiyu
    Chen, Yu
    Wei, Xiaoting
    Cao, Jun
    Lin, Jing
    Zhang, Peng
    Chen, Ling
    Cao, Xiao
    Chen, Yujun
    Guo, Jun
    Si, Lu
    CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4642 - 4648
  • [38] Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study
    Cheng, Yu
    Teng, Zan
    Zhang, Yanqiao
    Jin, Bo
    Zheng, Zhendong
    Man, Li
    Wang, Zhenghua
    Teng, Yuee
    Yu, Ping
    Shi, Jing
    Luo, Ying
    Wang, Ying
    Zhang, Jingdong
    Zhang, Huijuan
    Liu, Jiwei
    Chen, Hao
    Xiao, Jiawen
    Zhao, Lei
    Zhang, Lingyun
    Jiang, Yu
    Chen, Ying
    Zhang, Jian
    Wang, Chang
    Liu, Sa
    Qu, Jinglei
    Qu, Xiujuan
    Liu, Yunpeng
    BMC CANCER, 2024, 24 (01)
  • [39] Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II study
    Wu, X.
    Xia, L.
    Wang, J.
    Wang, C.
    Zhang, Q.
    Zhu, J.
    Rao, Q.
    Cheng, H.
    Liu, Z.
    Yin, Y.
    Ai, X.
    Gulina, K.
    Zheng, H.
    Luo, X.
    Chang, B.
    Li, L.
    Liu, H.
    Li, Y.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1506 - S1506
  • [40] EFFICACY AND SAFETY OF ZIMBERELIMAB (GLS-010) MONOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER: A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II STUDY
    Wu, Xiaohua
    Xia, Lingfang
    Wang, Jing
    Wang, Chunyan
    Zhang, Qingming
    Zhu, Jianqing
    Rao, Qunxian
    Cheng, Huijun
    Liu, Zheng
    Yin, Yongmei
    Ai, Xiaohong
    Gulina, Kurban
    Zheng, Hong
    Luo, Xiaoyong
    Chang, Baoping
    Li, Li
    Liu, Haiyan
    Li, Yunxia
    Lou, Ge
    Zhou, Qi
    Zhu, Yanling
    Xiao, Zemin
    Tong, Jiandong
    Wang, Ke
    Chen, Jie
    Wang, Xia
    Song, Lijie
    Wei, Zhixia
    Ye, Yijing
    Zhu, Jiman
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A703 - A703
12345